<?xml version="1.0" encoding="UTF-8"?>
<p>Metabolic syndrome is a serious and escalating worldwide public health threat that directly increases the risk of developing obesity, diabetes, atherosclerosis, and hypertension, or combinations [
 <xref rid="B1" ref-type="bibr">1</xref>]. These metabolic abnormalities are related to, among other enzymes, lipolytic enzymes such as pancreatic lipases, phospholipases, and proteases and metabolic enzymes like 
 <italic>β</italic>-glucosidase, 
 <italic>α</italic>-amylase, and xanthine oxidase (XO) [
 <xref rid="B2" ref-type="bibr">2</xref>]. The prevalence of the metabolic syndrome is increasing to epidemic proportions not only in the United States and the remainder of the urbanized world but also in developing nations [
 <xref rid="B3" ref-type="bibr">3</xref>]. In most countries, between 20% and 30% of the adult population suffer from metabolic syndrome [
 <xref rid="B4" ref-type="bibr">4</xref>]. Because of this high prevalence and the consequences of metabolic syndrome, which is an important contributor to the increase in cardiovascular and diabetes risks worldwide, special therapeutic attention should be devoted.
</p>
